QOP
JUNO

Quinn Opportunity Partners’s Juno Therapeutics, Inc. JUNO Stock Holding History

Quinn Opportunity Partners’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-9,900
Closed -$296K – 226
2017
Q2 		$296K Hold
9,900
– – 0.05% 137
2017
Q1 		$220K Buy
+9,900
New +$212K 0.05% 146
2016
Q4 		– Sell
-14,400
Closed -$432K – 160
2016
Q3 		$432K Buy
+14,400
New +$448K 0.16% 94

Other funds holding JUNO

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Quinn Opportunity Partners's JUNO Position: Q3 2017 in Review

Quinn Opportunity Partners sold out of Juno Therapeutics, Inc. (JUNO) in Q3 2017, closing a stake of 9,900 shares — an estimated $296K sold.

Quinn Opportunity Partners first reported a position in JUNO in Q3 2016 and held it in 3 quarters. The position peaked at $432K in Q3 2016. 210 funds tracked by Wall St. Rank hold JUNO as of Q3 2017.

  • Quinn Opportunity Partners reported no remaining Juno Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Quinn Opportunity Partners sold 9,900 Juno Therapeutics, Inc. shares in Q3 2017, an estimated $296K.
  • Quinn Opportunity Partners first reported a position in Juno Therapeutics, Inc. in Q3 2016 and held it in 3 quarters.
  • Quinn Opportunity Partners's Juno Therapeutics, Inc. position peaked at $432K in Q3 2016.
  • 210 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q3 2017.

Based on Quinn Opportunity Partners's 13F filing for Q3 2017, filed 14 Nov 2017.